Alpa Laboratories share news, announcements and annual reports
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Alpa Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2007
Last close ₹50.38down ₹2.24 (4.26%)BSE ₹49.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹52.62.
30 Oct: open ₹51.50, high ₹51.65, low ₹50.00
52-week range of traded prices to 30 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,77166.0% delivered
Alpa Laboratories disputes and clarifications
34 filed, newest first.
Jul 2026
Jun 2026
25 Jun · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
Apr 2026
9 Apr · Legal
The exchange asked on 8 Apr 2026
Mar 2025
6 Mar · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
May 2024
Mar 2024
18 Mar · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Jun 2023
8 Jun · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Mar 2023
9 Mar · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jan 2023
21 Jan · Legal
The exchange asked on 20 Jan 2023
Jan 2022
6 Jan · Legal
The exchange asked on 5 Jan 2022
Nov 2021
Jul 2021
14 Jul · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Apr 2021
12 Apr · Legal
The exchange asked on 9 Apr 2021
Feb 2021
17 Feb · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Aug 2020
8 Aug · Legal
The exchange asked on 4 Aug 2020
Jul 2020
28 Jul · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2020
13 Apr · Legal
The exchange asked on 9 Apr 2020
Jan 2020
22 Jan · Legal
The exchange asked on 20 Jan 2020
Nov 2019
13 Nov · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.5 Nov · Legal
The exchange asked on 5 Nov 2019
Sep 2019
Aug 2019
19 Aug · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2019
24 Jul · Legal
The exchange asked on 23 Jul 2019
Oct 2018
Jun 2018
May 2018
28 May · Legal
Exchange has sought clarification from Alpa Laboratories Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Consolidated audited review report not submitted. -3. Standalone Reconciliation of profit and loss not submitted -4. Standalone Reconciliation of Equity not submitted -5. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -6. Consolidated Reconciliation of profit and loss not submitted -7. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.
Dec 2017
18 Dec · Legal
Exchange has sought clarification from Alpa Laboratories Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted as per Schedule III to the Companies Act, 2013 -2. Segment details not submitted The response of the Company is awaited.
Sep 2017
Jul 2016
21 Jul · Legal
Exchange has sought clarification from Alpa Laboratories Limited with respect to announcement dated July 20, 2016, regarding the Board of Directors of the Company in its meeting held July 20, 2016 has Appointment of Mrs. Jyoti Jain as an Additional Non Executive Independent Director of the Company.On basis of above the Company is required to clarify following:1. Reason for change viz. appointment;2. Brief profile;The response of the Company is awaited.